| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 114.09M | 156K | 95K | 22K |
| Revenue Growth % | - | - | - | - | - | -1% | -0.39% | -0.77% |
| Cost of Goods Sold | 0 | 0 | 5.03M | 11.54M | 0 | 14.29M | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | 91.63% | - | - |
| Gross Profit | 0 | -1.5M | -5.03M | -11.54M | 114.09M | -14.14M | 95K | 22K |
| Gross Margin % | - | - | - | - | 1% | -90.63% | 1% | 1% |
| Gross Profit Growth % | - | - | -2.35% | -1.3% | 10.89% | -1.12% | 1.01% | -0.77% |
| Operating Expenses | 2K | 192.84M | 202.01M | 246.7M | 294.28M | 321.4M | 327.83M | 273.22M |
| OpEx % of Revenue | - | - | - | - | 2.58% | 2060.24% | 3450.86% | 12419.14% |
| Selling, General & Admin | 2K | 40.98M | 57.47M | 65.26M | 74.11M | 79.31M | 71.67M | 65.2M |
| SG&A % of Revenue | - | - | - | - | 0.65% | 508.37% | 754.45% | 2963.86% |
| Research & Development | 0 | 151.86M | 144.53M | 192.99M | 220.18M | 256.39M | 242.91M | 192.3M |
| R&D % of Revenue | - | - | - | - | 1.93% | 1643.51% | 2556.99% | 8740.86% |
| Other Operating Expenses | 0 | 0 | 0 | -11.54M | 0 | -14.29M | 13.24M | 15.72M |
| Operating Income | -2K | -192.84M | -202.01M | -258.24M | -180.19M | -335.54M | -327.74M | -273.2M |
| Operating Margin % | - | - | - | - | -1.58% | -2150.87% | -3449.86% | -12418.14% |
| Operating Income Growth % | - | -96420% | -0.05% | -0.28% | 0.3% | -0.86% | 0.02% | 0.17% |
| EBITDA | 22K | -191.34M | -196.98M | -246.7M | -169.74M | -321.24M | -313.54M | -259.56M |
| EBITDA Margin % | - | - | - | - | -1.49% | -2059.24% | -3300.4% | -11798.18% |
| EBITDA Growth % | - | -8698.36% | -0.03% | -0.25% | 0.31% | -0.89% | 0.02% | 0.17% |
| D&A (Non-Cash Add-back) | 24K | 1.5M | 5.03M | 11.54M | 10.45M | 14.29M | 14.2M | 13.64M |
| EBIT | -2K | -208.26M | -184.93M | -250.22M | -180.19M | -335.54M | -327.26M | -256.97M |
| Net Interest Income | 0 | 2.43M | 17.35M | 9.16M | 1.71M | 4.57M | 18.31M | 19.97M |
| Interest Income | 0 | 5.79M | 17.35M | 9.16M | 1.71M | 4.57M | 18.31M | 20.15M |
| Interest Expense | 0 | 3.36M | 0 | 0 | 0 | 0 | 0 | 181K |
| Other Income/Expense | 0 | -18.78M | 17.08M | 8.02M | -1.86M | -4.88M | 472K | 16.05M |
| Pretax Income | -24K | -211.62M | -184.93M | -250.22M | -182.05M | -340.41M | -327.26M | -257.15M |
| Pretax Margin % | - | - | - | - | -1.6% | -2182.14% | -3444.89% | -11688.5% |
| Income Tax | -24K | -117K | -331K | 0 | 0 | 0 | 0 | 443K |
| Effective Tax Rate % | 0.08% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -2K | -211.5M | -184.59M | -250.22M | -182.05M | -340.41M | -327.26M | -257.59M |
| Net Margin % | - | - | - | - | -1.6% | -2182.14% | -3444.89% | -11708.64% |
| Net Income Growth % | - | -105751.5% | 0.13% | -0.36% | 0.27% | -0.87% | 0.04% | 0.21% |
| Net Income (Continuing) | -2K | -211.5M | -184.59M | -250.22M | -182.05M | -340.41M | -327.26M | -257.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00 | -2.36 | -1.83 | -2.08 | -1.34 | -2.38 | -2.09 | -1.32 |
| EPS Growth % | - | - | 0.22% | -0.14% | 0.36% | -0.78% | 0.12% | 0.37% |
| EPS (Basic) | 0.00 | -2.36 | -1.83 | -2.08 | -1.34 | -2.38 | -2.09 | -1.32 |
| Diluted Shares Outstanding | 44.01M | 89.69M | 101.06M | 120.37M | 135.82M | 143.15M | 156.93M | 194.81M |
| Basic Shares Outstanding | 44.01M | 89.69M | 101.06M | 120.37M | 135.82M | 143.15M | 156.93M | 194.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 0 | 467.98M | 544.58M | 845.13M | 471.32M | 528.82M | 459.12M | 303.39M |
| Cash & Short-Term Investments | 0 | 721.35M | 530.53M | 827.91M | 457.3M | 517.32M | 448.7M | 292.48M |
| Cash Only | 0 | 721.35M | 175.13M | 183.35M | 173.31M | 61.9M | 83.16M | 75.22M |
| Short-Term Investments | 0 | 0 | 355.41M | 644.56M | 283.99M | 455.42M | 365.54M | 217.26M |
| Accounts Receivable | 0 | 3.11M | 2.4M | 0 | 0 | 0 | 1.7M | 1.9M |
| Days Sales Outstanding | - | - | - | - | - | - | 6.53K | 31.52K |
| Inventory | 0 | -261.97M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | -2.4M | 0 | 0 | 11.5M | 0 | 9.01M |
| Total Non-Current Assets | 0 | 305.87M | 173.23M | 382.7M | 579.5M | 292.75M | 183.72M | 245.32M |
| Property, Plant & Equipment | 0 | 41.61M | 100.94M | 160.13M | 181.02M | 196.43M | 163.18M | 131.26M |
| Fixed Asset Turnover | - | - | - | - | 0.63x | 0.00x | 0.00x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 754K | 151K | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 261.97M | 63.21M | 207.95M | 382.38M | 76.47M | 3.65M | 80.67M |
| Other Non-Current Assets | 0 | 1.54M | 8.92M | 14.62M | 16.11M | 19.86M | 16.9M | 33.39M |
| Total Assets | 0 | 773.86M | 717.8M | 1.23B | 1.05B | 821.58M | 642.84M | 548.71M |
| Asset Turnover | - | - | - | - | 0.11x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | - | - | -0.07% | 0.71% | -0.14% | -0.22% | -0.22% | -0.15% |
| Total Current Liabilities | 2K | 29.46M | 33.08M | 94.32M | 47.91M | 53.73M | 37.08M | 35.52M |
| Accounts Payable | 0 | 12.34M | 9.25M | 10.39M | 10.26M | 13.89M | 5.9M | 5.39M |
| Days Payables Outstanding | - | - | 671.62 | 328.6 | - | 354.66 | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1000K | 156K | 95K | 86K | 0 |
| Other Current Liabilities | 0 | 5.2M | 12.4M | 12.97M | 16.13M | 17.93M | 11.66M | 12.15M |
| Current Ratio | - | 15.89x | 16.46x | 8.96x | 9.84x | 9.84x | 12.38x | 8.54x |
| Quick Ratio | - | 24.78x | 16.46x | 8.96x | 9.84x | 9.84x | 12.38x | 8.54x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 41.23M | 55.7M | 53.89M | 77.72M | 100.97M | 93.53M | 91.01M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 34.46M | 51.35M | 50.81M | 69.93M | 95.12M | 88.35M | 83.25M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 6.78M | 4.35M | 3.08M | 7.79M | 5.85M | 5.18M | 7.76M |
| Total Liabilities | 2K | 70.69M | 88.78M | 148.21M | 125.63M | 154.7M | 130.6M | 126.53M |
| Total Debt | 0 | 34.46M | 53.03M | 53.78M | 73.13M | 101.12M | 95.12M | 90.76M |
| Net Debt | 0 | -686.89M | -122.1M | -129.57M | -100.19M | 39.22M | 11.97M | 15.54M |
| Debt / Equity | - | 0.05x | 0.08x | 0.05x | 0.08x | 0.15x | 0.19x | 0.21x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -57.43x | - | - | - | - | - | -1509.39x |
| Total Equity | -2K | 703.16M | 629.02M | 1.08B | 925.2M | 666.88M | 512.23M | 422.18M |
| Equity Growth % | - | 351583% | -0.11% | 0.72% | -0.14% | -0.28% | -0.23% | -0.18% |
| Book Value per Share | -0.00 | 7.84 | 6.22 | 8.97 | 6.81 | 4.66 | 3.26 | 2.17 |
| Total Shareholders' Equity | -2K | 703.16M | 629.02M | 1.08B | 925.2M | 666.88M | 512.23M | 422.18M |
| Common Stock | 26K | 121K | 124K | 140K | 142K | 144K | 169K | 212K |
| Retained Earnings | -23K | -211.53M | -396.12M | -646.34M | -894.55M | -1.23B | -1.56B | -1.82B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5K | 306K | 1.15M | 268K | -2.57M | -9.93M | -955K | -89K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 0 | -44.65M | -137.35M | -115.09M | -184.81M | -220.52M | -237.73M | -200.3M |
| Operating CF Margin % | - | - | - | - | -1.62% | -1413.58% | -2502.45% | -9104.55% |
| Operating CF Growth % | - | - | -2.08% | 0.16% | -0.61% | -0.19% | -0.08% | 0.16% |
| Net Income | -24K | -211.5M | -184.59M | -250.22M | -257M | -332.63M | -327.26M | -257.59M |
| Depreciation & Amortization | 0 | 1.5M | 5.03M | 7.59M | 10.45M | 14.29M | 14.2M | 13.64M |
| Stock-Based Compensation | 0 | 18.57M | 46.06M | 65.26M | 80.82M | 83.6M | 65.95M | 51.74M |
| Deferred Taxes | 0 | -117K | -331K | 4.4M | 10.4M | 8.08M | 0 | 443K |
| Other Non-Cash Items | 0 | 134.81M | 3.36M | 3.96M | 2.61M | 2.43M | 24.69M | 16.26M |
| Working Capital Changes | 24K | 12.1M | -6.88M | 53.92M | -32.09M | 3.71M | -15.3M | -24.8M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 8.8M | -985K | 615K | -767K | 4.87M | -7.5M | -503K |
| Cash from Investing | 0 | -632.8M | 164.08M | -505.12M | 163.66M | 106.16M | 163.29M | 75.69M |
| Capital Expenditures | 0 | -3.23M | -50.79M | -65.96M | -21.45M | -5.19M | -1.52M | -694K |
| CapEx % of Revenue | - | - | - | - | 0.19% | 33.28% | 15.96% | 31.55% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -2.1M | 0 | -439.17M | 0 | 111.35M | 0 | 0 |
| Cash from Financing | 0 | 771.18M | 58.96M | 633.59M | 11.96M | 2.95M | 95.69M | 116.67M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 654.34M | 4.74M | 11.66M | 0 | 0 | 4.58M | 2.28M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | 0 | -47.89M | -188.14M | -181.05M | -206.26M | -225.71M | -239.25M | -200.99M |
| FCF Margin % | - | - | - | - | -1.81% | -1446.86% | -2518.41% | -9136.09% |
| FCF Growth % | - | - | -2.93% | 0.04% | -0.14% | -0.09% | -0.06% | 0.16% |
| FCF per Share | - | -0.53 | -1.86 | -1.50 | -1.52 | -1.58 | -1.52 | -1.03 |
| FCF Conversion (FCF/Net Income) | - | 0.21x | 0.74x | 0.46x | 1.02x | 0.65x | 0.73x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -60.16% | -27.71% | -29.29% | -18.16% | -42.76% | -55.51% | -55.13% |
| Return on Invested Capital (ROIC) | - | -1778.11% | -57.92% | -26.59% | -15.23% | -32.87% | -39.96% | -42.6% |
| Gross Margin | - | - | - | - | 100% | -9063.46% | 100% | 100% |
| Net Margin | - | - | - | - | -159.57% | -218214.1% | -344489.47% | -1170863.64% |
| Debt / Equity | - | 0.05x | 0.08x | 0.05x | 0.08x | 0.15x | 0.19x | 0.21x |
| Interest Coverage | - | -57.43x | - | - | - | - | - | -1509.39x |
| FCF Conversion | - | 0.21x | 0.74x | 0.46x | 1.02x | 0.65x | 0.73x | 0.78x |
| Revenue Growth | - | - | - | - | - | -99.86% | -39.1% | -76.84% |
| 2024 | |
|---|---|
| License | 4.6M |
| License Growth | - |
Allogene Therapeutics, Inc. (ALLO) reported $0.0M in revenue for fiscal year 2024.
Allogene Therapeutics, Inc. (ALLO) saw revenue decline by 76.8% over the past year.
Allogene Therapeutics, Inc. (ALLO) reported a net loss of $212.0M for fiscal year 2024.
Allogene Therapeutics, Inc. (ALLO) has a return on equity (ROE) of -55.1%. Negative ROE indicates the company is unprofitable.
Allogene Therapeutics, Inc. (ALLO) had negative free cash flow of $159.0M in fiscal year 2024, likely due to heavy capital investments.